

**Recommendations of the SEC (Cardiovascular) made in its 14<sup>th</sup>/24 meeting held on 13.08.24 at CDSCO (HQ), New Delhi:**

S. No	File Name & Drug Name, Strength	Firm Name	Recommendations
<b>GCT Division</b>			
1.	CT/37/24 Online Submission (33224)  Ravulizumab 10mg/mL (300mg/ 30mL)	M/s. AstraZeneca Pharma India Limited	The firm presented protocol amendment 2.0 dated 28 March 2024 protocol no. D928DC00001.  After detailed deliberation, the committee recommended for approval of protocol amendment as presented by the firm
2.	CT/13/24 Online Submission (41557)  Baxdrostat Tablets 1mg/ 2mg	M/s. AstraZeneca Pharma India Limited	In light of earlier SEC recommendation on 12.06.24, the firm presented phase 3 clinical trial protocol no. D6970C00008, CSP version 1.0 dated 27 October 2023 After detailed deliberation, the committee recommended for grant of permission to conduct the trial as presented by the firm with condition that newly added sites shall have cardiologist as PI.
3.	CT/77/22 Online Submission (33821)  Crovalimab 170 mg/ml Crovalimab 340 mg/2m	M/s. Roche Products (India) Private Limited	The firm presented proposal for increase in Indian patient sample size from 6 to 14 patients in the ongoing protocol no. BO42354. After detailed deliberation, the committee accepted the increase in Indian patient sample size from 6 to 14 patients with subject to condition that safety data of first 6 participants from India shall be submitted.
<b>Biological Division</b>			
4.	E. 45882  Andexanet alfa powder for solution for infusion 200 mg vial	M/s. AstraZeneca Pharma India Limited	The firm presented the proposal for waiver of Phase IV clinical study for the drug Andexanet alfa powder for solution for infusion 200 mg vial as per the condition stipulated in the issued clinical permission Form CT-20 with justification that non-covenant from sites for the participation in Phase IV study due to low incidence occurrence of Factor Xa Inhibitor associated bleeding. Firm has proposed for the conduct of active surveillance to report the safety and tolerability of the drug. After detailed deliberation, the committee agreed for the waiver of Phase IV study and recommended to conduct the post marketing surveillance study.

S. No	File Name & Drug Name, Strength	Firm Name	Recommendations
			Accordingly, the firm is required to submit the active post marketing surveillance study protocol to CDSCO for further evaluation by the committee with in two months.
<b>Medical Devices Division</b>			
5.	F.No.29/Misc./03/2023-DC (287) (Part-1)or File No.: (MED-14/8/2024-eoffice)  Symplcity Spyril	M/s. Medtronic Pvt. Ltd	The firm presented the proposal requesting to waive one of the conditions of approval granted in Form MD-27 and Form MD-15 for conduct of Post market clinical investigation of the said device. The firm presented the proposal for participation of Indian patient data in their Global Registry program. After detailed deliberation, the committee did not consider the proposal as the said registry is part of Post marketing surveillance, it is not a controlled clinical study. The expert further opined that the device does not have Clinical evidence in the Indian population being the product as an Investigational medical device. Therefore, the committee concluded that the firm shall submit Post market clinical investigation protocol along with statistically significant patients, within 3 months to CDSCO for necessary action in the matter.
<b>BA/BE Division</b>			
6.	BABE/CT05/FF/2024/42427  FDC of Torsemide 24 mg ER and Spironolactone 30 mg tablets	M/s. Syngene International Limited	In light of the earlier SEC recommendation dated 12/06/2024, the firm presented justification/evidence for proposed FDC and clinical report of relevant studies before the committee.  After detailed deliberation, the committee recommended for grant of permission to conduct the proposed Bioavailability study for export purpose only as presented by the firm.
<b>FDC Division</b>			
7.	FDC/MA/23/000195  Bisoprolol Fumarate IP 5mg/5mg +	M/s. Servier India Pvt. Ltd.	In the light of earlier SEC recommendation dated 20.12.2023, the firm presented the proposal along with BE study report before the committee.

S. No	File Name & Drug Name, Strength	Firm Name	Recommendations
	Perindopril Arginine 5mg/10mg film coated bilayer tablet		<p>After detailed deliberation, the committee considered the BE study report and recommended for grant of permission to manufacture and market of the FDC with the condition to conduct the Phase IV clinical trial.</p> <p>Accordingly, the firm should submit Phase IV clinical trial protocol to CDSCO within 3 months of approval of the FDC for review by the committee.</p>
8.	FDC/MA/24/000002  Sacubitril + Valsartan (as sodium salt complex) 50mg (24mg+26mg)/100mg(49mg+51mg)/200mg(97mg + 103mg) Film coated sustained release tablet	M/s.Exemed Pharmaceuticals	<p>In the light of earlier SEC recommendation dated 04.04.2024, the firm presented the proposal along with BE study report before the committee.</p> <p>After detailed deliberation, the committee opined that the firm should explain the variability of the kinetic data of the BE study report.</p> <p>Accordingly, the firm should submit above data to CDSCO for further review by the committee along with Phase III clinical trial protocol.</p>
9.	FDC/MA/24/000138  Torsemide IP 10mg/20mg + Eplerenone IP 25mg/25mg uncoated Tablets	M/s.Exemed Pharmaceuticals	<p>The firm presented the proposal before the committee along with BE study protocol &amp; Phase III clinical trial protocol.</p> <p>After detailed deliberation, the committee recommended for conduct of BE study and w.r.t to Phase III CT study the committee recommended for conduct Phase III CT study with following conditions:</p> <ol style="list-style-type: none"> <li>1. Primary endpoint should be "Atleast one class improvement in NYHA functional class."</li> <li>2. Ejection fraction should be less than 40 % in inclusion criteria.</li> </ol> <p>Accordingly, revised Phase III CT protocol should be submitted to CDSCO, for review. After approval from CDSCO, the firm should submit Phase III Clinical</p>

S. No	File Name & Drug Name, Strength	Firm Name	Recommendations
			<p>trial report.</p> <p>The result of the BE study should be presented for review by the SEC before initiation of the Phase III clinical trial.</p>
10.	<p>FDC/MA/24/000146</p> <p>Bisoprolol Fumarate IP 2.5mg/5mg/2.5mg/5mg + Telmisartan IP 40mg/40mg/ 40mg/40mg + Chlorthalidone IP 6.25mg/6.25mg /12.5mg/12.5mg film coated tablet</p>	<p>M/s. Akums Drugs &amp; Pharmaceuticals Ltd.</p>	<p>The firm presented the proposal before the committee along with BE study protocol &amp; Phase III clinical trial protocol for the strength i.e. Bisoprolol Fumarate 5mg + Telmisartan 40mg + Chlorthalidone 12.5mg tablet.</p> <p>After detailed deliberation, the committee recommended for conduct of the BE study with condition:</p> <ol style="list-style-type: none"> <li>1. Sample size should be 32-37.</li> <li>2. Anemia with hemoglobin &lt;10g/dL in Exclusion criteria.</li> </ol> <p>Further, the committee opined that the firm should submit revised Phase III clinical trial Protocol which should be scientifically structured.</p> <p>Accordingly, the firm should submit revised BE study protocol to CDSCO. After approval from CDSCO, the firm should submit BE study report for further review by the committee along with revised Phase III clinical trial protocol.</p>
11.	<p>FDC/MA/24/000171</p> <p>Bisoprolol Fumarate IP 5mg + Cilnidipine IP 10mg tablet</p>	<p>M/s. Unique Pharmaceutical Laboratories</p>	<p>The firm presented the proposal before the committee along with BE study protocol &amp; Phase III clinical trial protocol.</p> <p>After detailed deliberation, the committee recommended for conduct of the BE study &amp; Phase III clinical trial.</p> <p>The result of the BE study should be presented for review by SEC before initiation of the Phase III clinical trial.</p>
12.	<p>FDC/MA/24/000177</p> <p>Dapagliflozin Propanediol</p>	<p>M/s. Eris Lifesciences Limited</p>	<p>The firm presented the proposal along with justification for BE and Phase III CT waiver before the committee.</p>

S. No	File Name & Drug Name, Strength	Firm Name	Recommendations
	Monohydrate eq. to Dapagliflozin 10mg/10mg/10mg/10mg + Bisoprolol Fumarate 1.25mg/2.5mg/5mg/10mg + Sacubitril and Valsartan as Sodium salt complex 100mg/100mg/200mg/200mg film coated tablet		<p>After detailed deliberation, the committee considered the request for BE and Phase III CT waiver and recommended for grant of permission for manufacturing and marketing of the FDC with the condition to conduct the Phase IV clinical trial.</p> <p>Accordingly, the firm should submit Phase IV clinical trial protocol to CDSCO within 3 months of approval of the FDC for review by the committee.</p>